207305-60-0

Basic information

• Product Name: Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)- (9CI)
• Synonyms: Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)- (9CI);BOC-(S)-HABA;(2S)-4-[[(tert-Butoxy)carbonyl]amino]-2-hydroxybutanoic acid;Boc-s-HABA Butanoic acid,4-[[(1,1-diMethylethoxy)carbonyl]aMino]-2-hydroxy-, (2S)- (9CI);Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy
• CAS NO: 207305-60-0
• Molecular Formula: C₉H₁₇NO₅
• Molecular Weight: 219.23498
• Product Categories: N-BOC
• Mol File: 207305-60-0.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 422.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.204±0.06 g/cm3(Predicted)
• PKA: 3.74±0.10(Predicted)
• CAS DataBase Reference: Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)- (9CI)(207305-60-0)
• EPA Substance Registry System: Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)- (9CI)(207305-60-0)

Safety Data

• Hazardous Substances Data: 207305-60-0(Hazardous Substances Data)

Usage

Description

Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)(9CI) is a complex organic compound with a unique molecular structure. It is characterized by its butanoic acid backbone, which is modified with a specific arrangement of functional groups. Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)(9CI) is an enantiomer with the (2S)-configuration, indicating that it has a specific spatial arrangement of atoms in its molecule.

Uses

Used in Pharmaceutical Industry:
Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)(9CI) is used as an intermediate in the synthesis of Plazomicin Sulfate (P579505), the acidic salt of Plazomicin (P579500). Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negative pathogens. Butanoic acid, 4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, (2S)(9CI) plays a crucial role in the development of new antibiotics to combat multidrug-resistant bacteria, such as Klebsiella pneumoniae and Escherichia coli.

Upstream product

• 3938-83-8 (S)-4-amino-2-hydroxybutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 371193-49-6 2-benzyloxy-4-tert-butoxycarbonylamino-butyric acid 
• 1154760-97-0 6'-PNZ-2'-guanidinium-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154760-56-1 6'-PNZ-2'-(N-phthalimido-2-amino-ethylsulfonamide)-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154760-48-1 6'-PNZ-2'-(N-phthalimido-3-amino-propyl)-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154758-71-0 6',2'-diPNZ-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154760-35-6 6'-PNZ-2'-(N-Boc-N-methyl-amino-acetyl)-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154758-62-9 tert-butyl ((2R,3R,4R,5R)-2-(((1S,2S,3R,4S,6R)-4-((tert-butoxycarbonyl)amino)-6-((S)-4-((tert-butoxycarbonyl)amino)-2-hydroxybutanamido)-3-(((2S,3R)-3-((tert-butoxycarbonyl)amino)-6-(((((4-nitrobenzyl)oxy)carbonyl)amino)methyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-3,5-dihydroxy-5-methyltetrahydro-2H-pyran-4-yl)(methyl)carbamate 
• 1154758-73-2 6'-PNZ-3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1154758-72-1 3,3''-diBoc-1-(N-Boc-4-amino-2(S)-hydroxy-butyryl)-sisomicin 
• 1346507-60-5 C₄₆H₇₅N₇O₁₉ 

Relevant articles and documents

Pleuromutilin compounds for treating novel coronavirus pneumonia secondary bacterial infectious diseases

The present invention relates to novel pleuromutilin compounds, and a pharmaceutical composition and a use method thereof. Furthermore, the present invention also relates to a therapeutic method for treating bacterial infections, including infections caused by resistant microorganisms including multiple resistant microorganisms. The method and the compounds for treating secondary bacterial infectious diseases of novel coronavirus (COVID-19 or SARS-Cov-2) pneumonia, and the pharmaceutical composition of the compounds are especially provided, and provide scientific and technological support forwin-win new coronapneumonia epidemic prevention and control obstructing warfare.

Preparation method of pradimicin antibiotics

The invention provides a preparation method of pradimicin antibiotics, belonging to the field of pharmaceutical chemistry and pharmaceutical engineering. The preparation method comprises the followingsteps: freeing of sisomicin, protection of amino, selective introduction of protective groups, deprotection of amino, and the like. The preparation method is suitable for industrial production, thushaving good market prospects.

Light-triggered intramolecular cyclization in poly(lactic- co -glycolic acid)-based polymers for controlled degradation

Polylactide (PLA) and poly(dl-lactide-co-glycolide) (PLGA) are two prominent FDA-approved polymers because of their useful biodegradation into largely innocuous substances. Their hydrolytic degradation is slow and offers minimal control over degradation kinetics, especially in the minutes time scale. However, molecular engineering of their structures could allow triggered degradation. We have synthesized, by ring-opening polymerization (ROP), a series of PLGA-based polymers containing pendant nucleophiles protected with photocleavable groups. Upon deprotection, two of the polymers degrade rapidly via intramolecular cyclization into small molecules. Nanoparticles formulated from these polymers undergo rapid structural changes in response to UV light. This work introduces a novel polymeric structure to enable rapid on-demand degradation and expands the library of polymers that degrade by cyclization.